ST8SIA3 encodes an alpha-2,8-sialyltransferase that catalyzes the transfer of sialic acid onto terminal sialic acids of glycoproteins and glycolipids, preferentially forming oligosialic and polysialic acid structures on N-linked oligosaccharides including those of FETUB, AHSG, and alpha-2,3-sialylated glycosphingolipids. The enzyme plays a critical role in striatal function by mediating formation of di- and trisialylated glycotopes that regulate protein distribution in lipid rafts and modulate protein interactions. ST8SIA3 is functionally significant in cancer biology, particularly in glioblastoma. The enzyme synthesizes A2B5-positive glycolipids that promote cancer stem cell proliferation, migration, clonogenicity, and tumorigenesis; ST8SIA3 overexpression increases tumor growth while its inactivation reduces proliferation and extends survival in xenograft models 1. Neuraminidase treatment that removes the A2B5 epitope decreases tumor size and regrowth in organotypic models 2. ST8SIA3 is also dysregulated in endometrial cancer through aberrant promoter methylation, emerging as both a prognostic marker and potential therapeutic target 34. Additionally, ST8SIA3 expression correlates with shared molecular mechanisms in Alzheimer's disease and nonalcoholic fatty liver disease, suggesting broader relevance in neurodegeneration and metabolic disease 5. Beyond malignancy, ST8SIA3 has been implicated in cardiac regeneration and neural tissue restoration, with recent evidence suggesting its involvement in hypoxic adaptation 678. Current understanding of disease-specific therapeutic strategies targeting ST8SIA3 remains limited to preclinical approaches.